ARA290 (Cibinetide)

ARA290, also known as Cibinetide, is a specialized 11-amino acid peptide derived from the structure of erythropoietin (EPO). However, unlike its parent molecule, ARA290 does not stimulate the production of red blood cells (erythropoiesis). Instead, it selectively activates the Innate Repair Receptor (IRR), a complex that is upregulated during tissue injury and inflammatory stress. The primary function of ARA290 is to suppress the production of pro-inflammatory cytokines while activating cellular pathways that promote tissue repair, survival, and regeneration. This makes it a highly specialized tool for investigating chronic inflammatory conditions and neuropathic pain.

Scientific interest in ARA290 is heavily focused on its potential to treat small fiber neuropathy and other conditions characterized by persistent nerve damage and localized pain. By activating the innate repair mechanism, it helps to stabilize nerve fibers and reduce the inflammatory environment that contributes to abnormal pain signaling. Furthermore, studies have explored its benefits in organ protection, particularly in protecting the heart, kidneys, and pancreas from damage caused by chronic inflammation or ischemia. As a targeted anti-inflammatory and cytoprotective agent, ARA290 offers a unique therapeutic model for managing complex autoimmune and neuro-inflammatory diseases without the hematological complications associated with traditional EPO treatments.